Test ID NGPCM MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies
Shipping Instructions
Bone marrow aspirate samples must arrive within 4 days of collection.
Specimen Required
Submit only 1 of the following specimens:
Specimen Type: Bone marrow aspirate
Container/Tube: Lavender or pink top (EDTA) or yellow top (ACD)
Specimen Volume: 2 mL
Collection Instructions:
1. Minimum plasma cell percentage is 5%.
2. Invert several times to mix bone marrow.
3. Send bone marrow specimen in original tube. Do not aliquot.
4. Label specimen as bone marrow.
5. Fresh specimen is required for this test, as testing is performed on sorted cells.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerate
Specimen Type: Paraffin-embedded bone marrow clot
Container/Tube: Paraffin block
Collection Instructions:
1. Send 1 slide stained with hematoxylin and eosin.
2. Minimum plasma cell percentage is 20%.
3. Required amount of tissue area is at least 25mm(2).
4. Tissue should be fixed in 10% neutral-buffered formalin. Other fixatives are not acceptable.
5. Decalcified specimens (eg, bone marrow core biopsies) are not acceptable.
Specimen Stability Information: Ambient
Specimen Type: Tissue slide; bone marrow clot
Slides: 10 unstained slides
Container/ Tube: Transport in plastic slide holders.
Collection Instructions:
1. Send 10 unstained, nonbaked slides with 5-micron thick sections of tissue and 1 slide stained with hematoxylin and eosin
2. Minimum amount of plasma cells is 20%
3. Required amount of tissue area is at least 25mm(2).
4. Tissue should be fixed in 10% neutral-buffered formalin. Other fixatives are not acceptable.
5. Decalcified specimens (eg, bone marrow core biopsies) are not acceptable.
Specimen Stability Information: Ambient
Forms
1. Hematopathology Patient Information (T676)
2. If not ordering electronically, complete, print, and send an Hematopathology/Cytogenetics Test Request (T726) with the specimen.
Useful For
Evaluating multiple myeloma at the time of diagnosis and at disease relapse or when changing clinical management to provide prognostic information and determine potential therapeutic implications
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CSPMM | NGPCM Pre-Analysis Cell Sorting, BM | No | No |
Testing Algorithm
See Targeted Genes Interrogated by MayoComplete Plasma Cell Myeloma Next-Generation Sequencing for a list of the genes and exons targeted by this assay.
Special Instructions
Method Name
Next-Generation Sequencing (NGS)
Reporting Name
Plasma Cell Myeloma, NGS, VSpecimen Type
VariesSpecimen Minimum Volume
Bone marrow aspirate: 1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Reference Values
An interpretive report will be provided.
Day(s) Performed
Monday through Friday
Report Available
16 to 21 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81450
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
NGPCM | Plasma Cell Myeloma, NGS, V | 104241-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
MP074 | Specimen Type | 31208-2 |
MP075 | Indication for Test | 42349-1 |
618515 | NGPCM Result | No LOINC Needed |
618516 | Pathogenic Mutations Detected | 82939-0 |
618517 | Interpretation | 69047-9 |
618519 | Variants of Unknown Significance | 93367-1 |
618520 | Additional Information | 48767-8 |
618518 | Clinical Trials | 82786-5 |
618521 | Method Summary | 85069-3 |
618522 | Disclaimer | 62364-5 |
618523 | Panel Gene List | 36908-2 |
618524 | Reviewed By | 18771-6 |